US WorldMeds Receives Full U.S. FDA Approval of Tecelra (afamitresgene autoleucel) with an Expanded Indication, Extending the First Approved Engineered T-Cell Therapy for a Solid Tumor to Children as Young as 12
RegulatoryapprovedTecelraPositive
AI Analysis
Summary
US WorldMeds announced FDA full approval of Tecelra (afamitresgene autoleucel) with an expanded indication for pediatric patients as young as 12 years old with solid tumors, marking the first approved engineered T-cell therapy for solid tumors in children.
Outcome Details
Full U.S. FDA approval with expanded indication to include pediatric patients as young as 12 years old
Importance:9/10
Sentiment:
0.95
FDA approvalpediatric indicationengineered T-cell therapysolid tumorindication expansion
Read the original article
Published by Drugs.com New Drug Approvals on June 22, 2026 6:06 AM